Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lofexidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 16/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 16/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 16/20 | 0.97 |
| ▸ | HTR1A | P08908 | 2/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
| ▸ | MAOA | P21397 | 6/20 | 0.60 |
| ▸ | MAOB | P27338 | 6/20 | 0.60 |
| ▸ | NISCH | Q9Y2I1 | 5/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lofexidine SCHEMBL3500726 | 1.00 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Levlofexidine SCHEMBL947241 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Lofexidine SCHEMBL48960 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Dexlofexidine SCHEMBL124602 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Lofexidine SCHEMBL678553 | 0.97 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Lofexidine SCHEMBL22616208 | 0.97 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Lofexidine SCHEMBL22616152 | 0.91 | ADRA2A (0.85) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Lofexidine SCHEMBL22616113 | 0.91 | ADRA2A (0.85) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Lofexidine SCHEMBL22616174 | 0.91 | ADRA2A (0.85) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| Lofexidine SCHEMBL22616216 | 0.90 | ADRA2A (0.82) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 509 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2023078180-A1 | MINI-TABLET, AND PREPARATION METHOD THEREFOR AND FORMULATION THEREOF | 北京微智瑞医药科技有限公司 | 2023-05-11 | — | — | WO | claimed |
| EP-3891505-B1 | A METHOD FOR MEASURING A CONCENTRATION OF A BIOMARKER/ANALYTE IN BLOOD FROM MAMMALS | REDHOTDIAGNOSTICS AB (SE) | 2022-11-30 | — | — | EP | claimed |
| US-20220187304-A1 | A Method for Measuring a Concentration of a Biomarker-Analyte In Blood from Mammals | REDHOT DIAGNOSTICS AB (SE) | 2022-06-16 | — | — | US | claimed |
| CN-114231447-A | Preparation method and application of bacillus amyloliquefaciens microbial inoculum | 四川省烟草公司宜宾市公司 | 2022-03-25 | — | — | CN | claimed |
| CN-114129527-A | Miniature tablet and preparation method and preparation thereof | 北京微智瑞医药科技有限公司 | 2022-03-04 | — | — | CN | claimed |
| EP-3891505-A1 | A METHOD FOR MEASURING A CONCENTRATION OF A BIOMARKER/ANALYTE IN BLOOD FROM MAMMALS | REDHOTDIAGNOSTICS AB (SE) | 2021-10-13 | — | — | EP | claimed |
| WO-2020222192-A1 | METHODS OF TREATING PRURITUS | CLEXIO BIOSCIENCES LTD. (IL) | 2020-11-05 | — | — | WO | claimed |
| WO-2020156849-A1 | A METHOD FOR MEASURING A CONCENTRATION OF A BIOMARKER/ANALYTE IN BLOOD FROM MAMMALS. | REDHOTDIAGNOSTICS AB (SE) | 2020-08-06 | — | — | WO | claimed |
| EP-3513782-A1 | GEL FORMULATIONS FOR ORAL ADMINISTRATION OF DRUGS, IN PARTICULAR TO DYSPHAGIC PATIENTS | Universita' Degli Studi Di Camerino (IT) | 2019-07-24 | — | — | EP | claimed |
| CN-1568979-A | Dripping pills of lofexidine hydrochloride and its preparation method | NANCHANG HELIOEAST SCIENCE & TECHNOLOGY CO LTD (CN) | 2005-01-26 | — | — | CN | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| WO-1999055334-A1 | USE OF LOFEXIDINE FOR TREATING CHRONIC PELVIC PAIN IN WOMEN | BRITANNIA PHARMACEUTICALS LIMITED (GB) | 1999-11-04 | — | — | WO | claimed |
| CN-1230408-A | Compound alkaloid terpene hydrochloride analgesic preparation | KANGYUAN ALKALOID CO LTD (CN) | 1999-10-06 | — | — | CN | claimed |
| EP-0156163-B1 | PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF HYPERTENSION AND THROMBOEMBOLIC DISEASES | A. Nattermann & Cie. GmbH (DE) | 1988-11-09 | — | — | EP | claimed |
| US-4746660-A | Process for reducing reflex tachycardia in the treatment of hypertension employing a combination of a diazacyclopentene derivative and a pyridazinone derivative | A. Natternabb & CIE GmbH (DE) | 1988-05-24 | — | — | US | claimed |
| US-4661487-A | CARDIOVASCULAR DISORDERS | A. NATTERMANN & CIE GMBH (DE) | 1987-04-28 | — | — | US | claimed |
| EP-0082364-B1 | (+)-2-(1-(2,6-DICHLOROPHENOXY)-ETHYL)-1,3-DIAZACYCLOPENT-2-ENE, PROCESS FOR ITS PREPARATION AND ITS USE IN PHARMACEUTICAL COMPOSITIONS | A. Nattermann & Cie. GmbH (DE) | 1986-04-23 | — | — | EP | claimed |
| EP-0156163-A1 | Pharmaceutical product for the treatment of hypertension and thromboembolic diseases | A. Nattermann & Cie. GmbH (DE) | 1985-10-02 | — | — | EP | claimed |
| US-4443464-A | (+)-2-[1-(2,6-Dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene and the method for the treatment of human beings suffering from nervous disarrangements, in particular migraine | A. NATTERMANN & CIE GMBH (DE) | 1984-04-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | ADRA2A 396/4885ADRA2B 276/4885ADRA2C 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.